GB9914744D0 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
GB9914744D0
GB9914744D0 GBGB9914744.9A GB9914744A GB9914744D0 GB 9914744 D0 GB9914744 D0 GB 9914744D0 GB 9914744 A GB9914744 A GB 9914744A GB 9914744 D0 GB9914744 D0 GB 9914744D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic agents
therapeutic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9914744.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll GmbH filed Critical Knoll GmbH
Priority to GBGB9914744.9A priority Critical patent/GB9914744D0/en
Publication of GB9914744D0 publication Critical patent/GB9914744D0/en
Priority to SK1824-2001A priority patent/SK18242001A3/sk
Priority to HU0201878A priority patent/HUP0201878A3/hu
Priority to CN00809372A priority patent/CN1358092A/zh
Priority to EP00940379A priority patent/EP1187606A1/en
Priority to CA002375972A priority patent/CA2375972A1/en
Priority to BR0011880-0A priority patent/BR0011880A/pt
Priority to MXPA01012936A priority patent/MXPA01012936A/es
Priority to RU2002102076/14A priority patent/RU2229289C2/ru
Priority to CZ20014613A priority patent/CZ20014613A3/cs
Priority to IL14707900A priority patent/IL147079A0/xx
Priority to PCT/EP2000/005542 priority patent/WO2001000205A1/en
Priority to JP2001505914A priority patent/JP2003503349A/ja
Priority to KR1020017016575A priority patent/KR20020015357A/ko
Priority to PL00352402A priority patent/PL352402A1/xx
Priority to TR2001/03699T priority patent/TR200103699T2/xx
Priority to AU55332/00A priority patent/AU5533200A/en
Priority to BG106180A priority patent/BG106180A/bg
Priority to ZA200109989A priority patent/ZA200109989B/xx
Priority to NO20016224A priority patent/NO20016224L/no
Priority to HK03100246.9A priority patent/HK1049278A1/zh
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB9914744.9A 1999-06-24 1999-06-24 Therapeutic agents Ceased GB9914744D0 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GBGB9914744.9A GB9914744D0 (en) 1999-06-24 1999-06-24 Therapeutic agents
AU55332/00A AU5533200A (en) 1999-06-24 2000-06-16 Pharmaceutical composition containing sibutramine and orlistat
IL14707900A IL147079A0 (en) 1999-06-24 2000-06-16 Pharmaceutical composition containing sibutramine and orlistat
JP2001505914A JP2003503349A (ja) 1999-06-24 2000-06-16 シブトラミンおよびオルリステートを含有する医薬品組成物
CN00809372A CN1358092A (zh) 1999-06-24 2000-06-16 含有西布曲明和奥利司他的药物组合物
EP00940379A EP1187606A1 (en) 1999-06-24 2000-06-16 Pharmaceutical composition containing sibutramine and orlistat
CA002375972A CA2375972A1 (en) 1999-06-24 2000-06-16 Pharmaceutical composition containing sibutramine and orlistat
BR0011880-0A BR0011880A (pt) 1999-06-24 2000-06-16 Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica
MXPA01012936A MXPA01012936A (es) 1999-06-24 2000-06-16 Composicion farmaceutica que contiene sibutramina y orlistat.
RU2002102076/14A RU2229289C2 (ru) 1999-06-24 2000-06-16 Фармацевтическая композиция, содержащая сибутрамин и орлистат
CZ20014613A CZ20014613A3 (cs) 1999-06-24 2000-06-16 Terapeutická činidla
SK1824-2001A SK18242001A3 (sk) 1999-06-24 2000-06-16 Terapeutické prípravky na báze sibutramínu vrátane jeho enantiomérov a farmaceuticky prijateľných solí a orlistatu a ich použitie
PCT/EP2000/005542 WO2001000205A1 (en) 1999-06-24 2000-06-16 Pharmaceutical composition containing sibutramine and orlistat
HU0201878A HUP0201878A3 (en) 1999-06-24 2000-06-16 Pharmaceutical composition containing sibutramine and orlistat
KR1020017016575A KR20020015357A (ko) 1999-06-24 2000-06-16 시부트라민 및 올리스타트를 포함하는 제약 조성물
PL00352402A PL352402A1 (en) 1999-06-24 2000-06-16 Pharmaceutical composition containing sibutramine and orlistat
TR2001/03699T TR200103699T2 (tr) 1999-06-24 2000-06-16 Sibutramin ve orlistat ihtiva eden farmakolojik bileşimler
BG106180A BG106180A (bg) 1999-06-24 2001-12-04 Фармацевтичен състав, съдържащ сибутрамин и орлистат
ZA200109989A ZA200109989B (en) 1999-06-24 2001-12-05 Pharmaceutical composition containing sibutramine and orlistat.
NO20016224A NO20016224L (no) 1999-06-24 2001-12-19 Farmasöytisk blanding inneholdende sibutramin og orlistat
HK03100246.9A HK1049278A1 (zh) 1999-06-24 2003-01-09 含有西布曲明和奧利司他的藥物組合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9914744.9A GB9914744D0 (en) 1999-06-24 1999-06-24 Therapeutic agents

Publications (1)

Publication Number Publication Date
GB9914744D0 true GB9914744D0 (en) 1999-08-25

Family

ID=10855955

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9914744.9A Ceased GB9914744D0 (en) 1999-06-24 1999-06-24 Therapeutic agents

Country Status (21)

Country Link
EP (1) EP1187606A1 (bg)
JP (1) JP2003503349A (bg)
KR (1) KR20020015357A (bg)
CN (1) CN1358092A (bg)
AU (1) AU5533200A (bg)
BG (1) BG106180A (bg)
BR (1) BR0011880A (bg)
CA (1) CA2375972A1 (bg)
CZ (1) CZ20014613A3 (bg)
GB (1) GB9914744D0 (bg)
HK (1) HK1049278A1 (bg)
HU (1) HUP0201878A3 (bg)
IL (1) IL147079A0 (bg)
MX (1) MXPA01012936A (bg)
NO (1) NO20016224L (bg)
PL (1) PL352402A1 (bg)
RU (1) RU2229289C2 (bg)
SK (1) SK18242001A3 (bg)
TR (1) TR200103699T2 (bg)
WO (1) WO2001000205A1 (bg)
ZA (1) ZA200109989B (bg)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
BRPI0517434A (pt) 2004-10-25 2008-10-07 Solvay Pharm Gmbh composições farmacêuticas compreendendo antagonistas do receptor canabinóide cb1 e abridores de canal de potássio para o tratamento de diabetes mellitus do tipo i, obesidade e estados relacionados
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
CA2663254C (en) 2006-09-15 2016-04-19 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
KR20080046601A (ko) * 2006-11-22 2008-05-27 에스케이케미칼주식회사 보관안정성이 우수한 시부트라민 함유 포접복합체
CN101890017A (zh) * 2009-05-22 2010-11-24 北京奥萨医药研究中心有限公司 含有西布曲明和他汀类降脂药物的药物组合物及其用途
MX336980B (es) * 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combinacion y composicion para el tratamiento de obesidad.
RU2642074C2 (ru) 2011-12-30 2018-01-24 Ревива Фармасьютикалс, Инк. Композиции, синтез и способы применения производных фенилциклоалкилметиламина

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727131D0 (en) * 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
SK18242001A3 (sk) 2003-02-04
BG106180A (bg) 2002-08-30
TR200103699T2 (tr) 2002-04-22
HK1049278A1 (zh) 2003-05-09
CA2375972A1 (en) 2001-01-04
MXPA01012936A (es) 2004-04-21
EP1187606A1 (en) 2002-03-20
HUP0201878A2 (hu) 2003-08-28
IL147079A0 (en) 2002-08-14
WO2001000205A1 (en) 2001-01-04
HUP0201878A3 (en) 2005-04-28
AU5533200A (en) 2001-01-31
NO20016224D0 (no) 2001-12-19
CZ20014613A3 (cs) 2003-04-16
CN1358092A (zh) 2002-07-10
RU2229289C2 (ru) 2004-05-27
KR20020015357A (ko) 2002-02-27
PL352402A1 (en) 2003-08-25
BR0011880A (pt) 2002-03-19
ZA200109989B (en) 2003-02-26
JP2003503349A (ja) 2003-01-28
NO20016224L (no) 2002-02-12

Similar Documents

Publication Publication Date Title
GB9911863D0 (en) Therapeutic agents
GB9905010D0 (en) Therapeutic agents
HK1200316A1 (en) Therapeutic microfoams
IL150030A0 (en) Therapeutic agents
GB9904786D0 (en) Therapeutic agents
GB9929685D0 (en) Therapeutic agents
GB9929687D0 (en) Therapeutic agents
GB9911881D0 (en) Therapeutic agents
GB9921351D0 (en) Therapeutic agents
GB9801234D0 (en) Therapeutic agents
PL339848A1 (en) Therapeutic agent against hypephosphataemia
GB9801210D0 (en) Therapeutic agents
AP9901436A0 (en) Therapeutic agents
GB9903476D0 (en) Therapeutic agents
GB9929569D0 (en) Therapeutic agents
GB9911802D0 (en) Therapeutic combination
GB9911803D0 (en) Therapeutic combination
GB9914744D0 (en) Therapeutic agents
GB9911804D0 (en) Therapeutic combination
GB9801202D0 (en) Therapeutic agents
GB9903119D0 (en) Therapeutic agents
IL147078A0 (en) Therapeutic agents
GB9914745D0 (en) Therapeutic agents
GB9902881D0 (en) Therapeutic agents
GB9914743D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)